American BioMed signs technology deal with US Surgical
This article was originally published in Clinica
American BioMed has granted US Surgical a 90-day option to buy ABM's technologies for stents, atherectomy catheters and toposcopic catheters. US Surgical paid $2 million for the option and will pay an additional $12 million on completion of the agreement, which includes all intellectual property rights for the technologies. The sale is subject to approval by American BioMed shareholders.
You may also be interested in...
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.
The Stark Law ban on self-referrals wouldn’t apply to some physician owners of advanced imaging facilities under a CMS final rule.
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.